The Regulator

3.7 million: that is how many 2028 tax returns Treasury expects to carry an excess Obamacare subsidy repayment under a proposed rule published October 15. The Internal Revenue Service (IRS) proposal would eliminate the cap on how much of an overpaid advance premium tax credit (APTC) a filer must pay back, for tax years beginning after December 31, 2025. Today the cap limits repayment for lower-income households; under the proposal the full excess is added to tax liability. The rule also drops the premium tax credit for lawfully present immigrants below 100% of the federal poverty level, adds enrollment verification requirements starting in 2028, and treats people shut out of Medicaid by the new work requirement as having other coverage, so they cannot claim the credit for those months. Treasury says about 15.6 million people are affected. Comments are due November 30; a telephonic hearing is December 8 at 10 a.m. Eastern. Confidence: High on the text; Med on the 3.7 million, which is Treasury’s own estimate. Sources: Federal Register proposed rule, Premium Tax Credit (REG-101576-26), Federal Register full text.

CMS says it found 189,000 Obamacare enrollees who are duplicated in Medicare, Medicaid or the Children’s Health Insurance Program (CHIP), or recorded as deceased, and projects $1.5 billion in savings over the next year. The Centers for Medicare & Medicaid Services (CMS) announced October 14 that flagged enrollees get 30 days to dispute the finding before their subsidies and plans end; for deceased enrollees, CMS contacts the individual or estate and allows the same 30 days. The agency says the checks now run at least twice a year, and that 2025 enforcement ended subsidies for about 551,000 people already covered by Medicaid. The $1.5 billion is a CMS projection of “potential” savings, not a realized figure, and the release’s claim that checks were paused for four years is the agency’s own characterization. Confidence: High on the numbers as reported; Low on the savings. Sources: CMS press release.

FDA expanded approval of Anktiva to BCG-unresponsive papillary bladder cancer on October 14. The Food and Drug Administration (FDA) approved Anktiva (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin (BCG) for adults with high-grade, papillary-only non-muscle invasive bladder cancer that has not responded to BCG. In a 77-patient study, 62% reached a complete response; of those, 58% held it at least 12 months and 40% at least 24 months. The label allows up to 37 months of treatment. FDA’s release does not give a price. The expansion rests on the earlier carcinoma in situ results plus evidence the two tumor types share key features, so the evidence base is indirect. Confidence: High. Sources: FDA press announcement.

FDA opened a rare disease framework initiative with a public meeting October 28. FDA says only about 5% of rare conditions have an approved treatment, and it wants a review approach fitted to each disease, product type and the evidence small patient populations can produce. Stated commitments include risk-based handling of manufacturing controls and pre-approval inspections, which is where small developers often get stuck. Possible outcomes include new guidance, regulatory revisions and organizational changes; no binding rule yet and no comment deadline stated. The meeting is at the White Oak campus, run with the Reagan-Udall Foundation. Confidence: High on the announcement; Low on any near-term effect. Sources: FDA press announcement.

FDA authorized four more emergency animal drugs against New World screwworm, a flesh-eating fly larva that threatens livestock and pets. The Federal Register notice published October 15 covers authorizations issued August 7 (Elanco, a topical for cattle, sheep, goats, swine and wildlife), August 13 (Zoetis, treatment in dogs), August 27 (Bimeda, prevention in cattle) and September 3 (Sergeant’s Pet Care, dogs and cats). They rest on the August 18, 2025 HHS determination of a significant potential public health emergency. For ranchers, the point is more approved tools while the pest threatens herds. The notice posted so far gives only the abstract and metadata, not the conditions of use. Confidence: High on the authorizations; Low on market impact. Sources: Federal Register notice, FDA-2026-N-0004.